<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02375958</url>
  </required_header>
  <id_info>
    <org_study_id>CPCA062X2101</org_study_id>
    <secondary_id>2014-003732-40</secondary_id>
    <nct_id>NCT02375958</nct_id>
  </id_info>
  <brief_title>PCA062 in pCAD-positive Tumors.</brief_title>
  <official_title>A Phase 1 Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intravenously in Adult Patients With p-CAD Positive Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A first-in-human sttudy using PCA062 in patients with p-CAD positive solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2015</start_date>
  <completion_date type="Anticipated">March 6, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 6, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of dose limiting toxicities</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of serious/adverse events</measure>
    <time_frame>Duration of study (each treatment cycle = 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter Cmax</measure>
    <time_frame>84 days</time_frame>
    <description>Cmax = the maximum concentration (peak) of the drug observed in the blood after a single administration of the drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of PCA062 anti-bodies</measure>
    <time_frame>84 days</time_frame>
    <description>The presence and/or concentration of the anti-bodies will be tested from the blood samples collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Duration of study (each treatment cycle = 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Duration of study (each treatment cycle = 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response</measure>
    <time_frame>Duration of study (each treatment cycle = 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic paramater Tmax</measure>
    <time_frame>84 days</time_frame>
    <description>Tmax = the time the drug takes to reach maximum (peak) concentration in the blood</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Triple Negative Breast Cancer, Head &amp; Neck Cancer, Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Head and Neck Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Esophageal Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCA062</intervention_name>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
    <arm_group_label>Head and Neck Cancer</arm_group_label>
    <arm_group_label>Esophageal Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male or female ≥ 18 years of age

          2. Documented pCAD expressing tumor cells with the exception of HNSCC and ESCC. An
             archived tumor sample collected within 36 months prior to baseline if available, or a
             new tumor biopsy sample must be available for molecular pre-screening.

          3. Consent for a tumor biopsy at screening

          4. Progressive disease and no effective therapy exists

          5. Measurable disease as per RECIST v1.1 criteria

          6. ECOG Performance status of ≤ 2

        Exclusion criteria:

          1. CNS metastatic involvement

          2. Clinically significant cardiac, respiratory, gastrointestinal, renal, hepatic or
             neurological conditions.

          3. A history of serious allergic reactions, which in the opinion of the investigator pose
             an increased risk of serious infusion reactions.

          4. Monocular vision or has media opacities or any other condition that precludes
             monitoring of the retina or the fundus, or has a history of ophthalmology exam with
             retina or cornea abnormalities

          5. Previously treated with anti-pCAD biologic therapies.

          6. Received anti-cancer therapies within the following time frames prior to the first
             dose of study treatment:

               -  Conventional cytotoxic chemotherapy: ≤4 weeks

               -  Biologic therapy (eg, antibodies), other than ADCs: ≤4 weeks

               -  Non-cytotoxic small molecule therapeutics: ≤5 T1/2 or ≤2 weeks (whichever is
                  longer)

               -  Other investigational agents: ≤4 weeks

               -  Radiation therapy (palliative setting is allowed.): ≤4 weeks

               -  Major surgery: ≤2 weeks

          7. Patient has out of range laboratory values defined as:

               -  Hematological values:

               -  Absolute neutrophil count (ANC) &lt;1.5 x 109/L

               -  Hemoglobin (Hgb) &lt;9 g/dL

               -  Platelets &lt;100 x 109/L

               -  Hepatic and renal function

               -  Total bilirubin &gt;1.5 x upper limit of normal (ULN). For patients with Gilbert's
                  syndrome, total bilirubin &gt;2.5 x ULN.

               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;3 x ULN for
                  patients without tumor involvement of the liver or &gt;5 x ULN for patients with
                  tumor involvement of the liver.

               -  Serum creatinine &gt;1.5 x ULN and/or measured creatinine clearance &lt; 40 ml/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly M Kelly</last_name>
      <phone>310-582-4069</phone>
      <email>KMKelly@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Zev A. Wainberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Rodriguez</last_name>
      <phone>713-792-7634</phone>
      <email>rodriguezk3@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Vivek Subbiah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tyson DeSutter</last_name>
      <phone>210-450-5956</phone>
      <email>desutter@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>John Sarantopoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCA062, Triple Negative Breast Cancer, Head &amp; Neck Cancer, Esophageal Cancer, pCAD, pcadherin, solid-tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

